Details of the Drug

General Information of Drug (ID: DMEBOFW)

Drug Name
Clofazimine
Synonyms
clofazimine; 2030-63-9; Lamprene; Lampren; Chlofazimine; Clofazimina; Clofaziminum; Clofaziminum [INN-Latin]; B 663 (Pharmaceutical); Clofazimina [INN-Spanish]; B-663; NSC-141046; G 30320; UNII-D959AE5USF; B 663 (VAN); C27H22Cl2N4; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; B 663; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; EINECS 217-980-2; CFZ; SMP2_000339; B 663, pharmaceutical; G-30320; Lamprene (TN); Liposome-encapsulated clofazimine; Clofazimine [USAN:INN:BAN]; G-30,320; Clofazimine (JAN/USP/INN); N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; (3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; Riminophenazine
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Mycobacterium infection 1B10-1B21 Investigative [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 473.4
Topological Polar Surface Area (xlogp) 7.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 0.41 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 8 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
57% of drug becomes completely available to its intended biological destination(s) [5]
Elimination
0.2% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 25 days [3]
Metabolism
The drug is metabolized via a hydrolytic deamination reaction followed by glucuronidation [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.03408 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.001 mg/mL [4]
Chemical Identifiers
Formula
C27H22Cl2N4
IUPAC Name
N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine
Canonical SMILES
CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
InChI
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
InChIKey
WDQPAMHFFCXSNU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2794
ChEBI ID
CHEBI:3749
CAS Number
2030-63-9
DrugBank ID
DB00845
TTD ID
D0S5UH
VARIDT ID
DR00669
INTEDE ID
DR0346
ACDINA ID
D00956

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Deoxyribonucleic acid (Bact DNA) TTS1W4A NOUNIPROTAC Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clofazimine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Clofazimine and Ivosidenib. Acute myeloid leukaemia [2A60] [32]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Midostaurin. Acute myeloid leukaemia [2A60] [33]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Idarubicin. Acute myeloid leukaemia [2A60] [33]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Arn-509. Acute myeloid leukaemia [2A60] [34]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Gilteritinib. Acute myeloid leukaemia [2A60] [33]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Oliceridine. Acute pain [MG31] [33]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Rivastigmine. Alzheimer disease [8A20] [35]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Clofazimine and Metronidazole. Amoebiasis [1A36] [36]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ivabradine. Angina pectoris [BA40] [34]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Clofazimine and Bepridil. Angina pectoris [BA40] [35]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Clofazimine and Dronedarone. Angina pectoris [BA40] [35]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Clofazimine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [37]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Cilostazol. Arterial occlusive disease [BD40] [33]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Posaconazole. Aspergillosis [1F20] [33]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Levalbuterol. Asthma [CA23] [38]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Terbutaline. Asthma [CA23] [39]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Pirbuterol. Asthma [CA23] [38]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Salbutamol. Asthma [CA23] [38]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Formoterol. Asthma [CA23] [39]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [34]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Desipramine. Attention deficit hyperactivity disorder [6A05] [33]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Ofloxacin. Bacterial infection [1A00-1C4Z] [33]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Clarithromycin. Bacterial infection [1A00-1C4Z] [33]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Clofazimine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [35]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Clofazimine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [40]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [33]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Norfloxacin. Bacterial infection [1A00-1C4Z] [33]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Levofloxacin. Bacterial infection [1A00-1C4Z] [33]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [33]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Telithromycin. Bacterial infection [1A00-1C4Z] [33]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Retigabine. Behcet disease [4A62] [33]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Eribulin. Breast cancer [2C60-2C6Y] [33]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lapatinib. Breast cancer [2C60-2C6Y] [33]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Bosutinib. Breast cancer [2C60-2C6Y] [33]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [33]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [39]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [38]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [39]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [39]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [39]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Isoproterenol. Conduction disorder [BC63] [38]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Halothane. Corneal disease [9A76-9A78] [33]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Sevoflurane. Corneal disease [9A76-9A78] [33]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Probucol. Coronary atherosclerosis [BA80] [33]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Clofazimine and Pasireotide. Cushing syndrome [5A70] [35]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Osilodrostat. Cushing syndrome [5A70] [33]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Clofazimine and Escitalopram. Depression [6A70-6A7Z] [35]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Clomipramine. Depression [6A70-6A7Z] [33]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Doxepin. Depression [6A70-6A7Z] [33]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Maprotiline. Depression [6A70-6A7Z] [33]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [35]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Ingrezza. Dystonic disorder [8A02] [41]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Solifenacin. Functional bladder disorder [GC50] [33]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Ketoconazole. Fungal infection [1F29-1F2F] [33]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [33]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [33]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Clofazimine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [42]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [35]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [33]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Clofazimine and Polyethylene glycol. Irritable bowel syndrome [DD91] [34]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Phenolphthalein. Irritable bowel syndrome [DD91] [36]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Clofazimine and Crizotinib. Lung cancer [2C25] [43]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Clofazimine and Ceritinib. Lung cancer [2C25] [35]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Clofazimine and Osimertinib. Lung cancer [2C25] [44]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Clofazimine and Selpercatinib. Lung cancer [2C25] [45]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Clofazimine and Lumefantrine. Malaria [1F40-1F45] [36]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Clofazimine and Halofantrine. Malaria [1F40-1F45] [36]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Clofazimine and Hydroxychloroquine. Malaria [1F40-1F45] [46]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Primaquine. Malaria [1F40-1F45] [33]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [33]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Clofazimine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [47]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Clofazimine and Vemurafenib. Melanoma [2C30] [35]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and LGX818. Melanoma [2C30] [48]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Clofazimine and Panobinostat. Multiple myeloma [2A83] [49]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Thalidomide. Multiple myeloma [2A83] [36]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Clofazimine and Siponimod. Multiple sclerosis [8A40] [36]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Clofazimine and Fingolimod. Multiple sclerosis [8A40] [35]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ozanimod. Multiple sclerosis [8A40] [50]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Romidepsin. Mycosis fungoides [2B01] [33]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Clofazimine and Nilotinib. Myeloproliferative neoplasm [2A20] [35]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Dasatinib. Myeloproliferative neoplasm [2A20] [33]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Promethazine. Nausea/vomiting [MD90] [33]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Granisetron. Nausea/vomiting [MD90] [33]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Ondansetron. Nausea/vomiting [MD90] [33]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Entrectinib. Non-small cell lung cancer [2C25] [33]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Clofazimine and Levomethadyl Acetate. Opioid use disorder [6C43] [34]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lofexidine. Opioid use disorder [6C43] [35]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Rucaparib. Ovarian cancer [2C73] [33]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Buprenorphine. Pain [MG30-MG3Z] [33]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Triclabendazole. Parasitic worm infestation [1F90] [33]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Pimavanserin. Parkinsonism [8A00] [51]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Famotidine. Peptic ulcer [DA61] [36]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Clofazimine and Macimorelin. Pituitary gland disorder [5A60-5A61] [52]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Clofazimine and Lefamulin. Pneumonia [CA40] [32]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Clofazimine and Ritodrine. Preterm labour/delivery [JB00] [38]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Degarelix. Prostate cancer [2C82] [34]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Clofazimine and ABIRATERONE. Prostate cancer [2C82] [34]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Enzalutamide. Prostate cancer [2C82] [34]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Relugolix. Prostate cancer [2C82] [34]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Bicalutamide. Prostate cancer [2C82] [34]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Levomepromazine. Psychotic disorder [6A20-6A25] [33]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Clofazimine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [53]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Quetiapine. Schizophrenia [6A20] [35]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Clofazimine and Mesoridazine. Schizophrenia [6A20] [36]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Aripiprazole. Schizophrenia [6A20] [36]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Clofazimine and Iloperidone. Schizophrenia [6A20] [35]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Paliperidone. Schizophrenia [6A20] [33]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Perphenazine. Schizophrenia [6A20] [33]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Clofazimine and Amisulpride. Schizophrenia [6A20] [54]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Asenapine. Schizophrenia [6A20] [35]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Clofazimine and Pimozide. Schizophrenia [6A20] [34]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Vardenafil. Sexual dysfunction [HA00-HA01] [33]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Clofazimine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [35]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [34]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [33]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Pitolisant. Somnolence [MG42] [33]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [33]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Lenvatinib. Thyroid cancer [2D10] [33]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Clofazimine and Cabozantinib. Thyroid cancer [2D10] [34]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Clofazimine and Papaverine. Tonus and reflex abnormality [MB47] [55]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Tacrolimus. Transplant rejection [NE84] [33]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [33]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Clofazimine and Procainamide. Ventricular tachyarrhythmia [BC71] [35]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Propafenone. Ventricular tachyarrhythmia [BC71] [33]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Clofazimine and Flecainide. Ventricular tachyarrhythmia [BC71] [33]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Clofazimine and Amiodarone. Ventricular tachyarrhythmia [BC71] [35]
⏷ Show the Full List of 126 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Butylated hydroxytoluene E00336 31404 Antioxidant
Ethyl vanillin E00178 8467 Flavoring agent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
methylparaben E00149 7456 Antimicrobial preservative
Propylparaben sodium E00567 23679044 Antimicrobial preservative
Ethylparaben E00177 8434 Antimicrobial preservative
Ferric oxide black E00522 16211978 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Soybean lecithin E00637 Not Available Other agent
Haematite red E00236 14833 Colorant
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clofazimine 100mg capsule 100mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019500.
2 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
3 FDA Approved Drug Products: Lamprene (clofazimine) oral capsules
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
8 Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26.
9 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
20 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
21 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
22 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
23 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
24 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
25 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
26 DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
27 On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
28 Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42.
29 Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
30 Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
31 Clinical pipeline report, company report or official report of MGB Biopharma.
32 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
33 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
34 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
35 Canadian Pharmacists Association.
36 Cerner Multum, Inc. "Australian Product Information.".
37 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
38 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
39 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
40 Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
41 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
42 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
43 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
46 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
47 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
48 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
49 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
51 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
52 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
53 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
54 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
55 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]